Explore
Kinase Inhibitor for Cancer Therapy
0 Ungluers have
Faved this Work
Login to Fave
Cancer is one of the leading causes of death worldwide, yet considerable efforts are still required to make this pathology curable. Despite the limits of available approaches, kinase inhibitors have marked a turning point in the treatment of different types of tumors. This class of compounds is the first oral targeted therapy approved for neoplasia, and about 30 compounds have entered the market in the last five years. Kinase inhibitors include small molecules and monoclonal antibodies and are endowed with fewer side effects than classical antitumor agents. The potential for application of this class of drugs is substantial, and this Special Issue focuses on the discovery and development of kinase inhibitors in terms of in silico studies, synthesis and identification of new compounds, drug delivery, formulation studies, and biological and pharmacokinetic evaluation.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 5 times via unglue.it ebook links.
- 5 - pdf (CC BY-NC-ND) at Unglue.it.
Keywords
- 3D tissue culture
- 3D tumor model
- ?? T cells
- ABC drug efflux transporter
- acute myeloid leukemia
- ADME
- Akt1
- aldo-keto reductase 1C3
- ALK
- Animal Models
- anthracycline
- anti-aging
- anticancer agents
- antiproliferative activity
- antitumor
- antitumor activity
- Apoptosis
- aptamer
- Autophagy
- binding mode/interactions
- Breast cancer
- c-Src/Abl dual inhibitors
- Cancer
- cancer therapy
- chemical inhibitors
- childhood cancer
- choline kinase
- cisplatin
- clinical trials
- CML
- CMV
- co-chaperone
- combinatorial chemotherapy
- computer-aided drug discovery
- curcumin
- cutaneous T-cell lymphoma
- Cytokines
- dasatinib
- diabetes
- drug resistance
- Drug Screening
- dual protein kinase inhibitors
- EGFR
- EGFR/PI3K/AKT/mTOR signaling
- ER stress
- erlotinib
- erufosine
- fragment
- gastric cancer
- Glioblastoma
- Heat shock proteins
- hepatocellular carcinoma
- heterocycle molecules
- HIV functional cure
- HIV-1
- Hsp90 inhibitor
- ibrutinib
- inhibitor
- innate immunity
- JAK
- JNK
- JNK3
- KAN0441571C
- kinase
- kinase allosteric inhibition
- kinase inhibitor
- kinase inhibitors
- kinase inhibitory activity
- kinases
- Lipid Metabolism
- lung tumors
- MCL
- MD simulation
- memory-like NK cells
- microtubule-destabilizing agents
- MNK1
- molecular docking
- molecular modeling
- multiple myeloma
- n/a
- Nanomedicine
- Nanotechnology
- Non-Small Cell Lung Cancer
- NSCLC
- ON-01910.Na
- PERK
- pharmacological uses
- PI3K/AKT
- PI3K?
- PLK1
- poloxamers
- polymeric nanoparticles
- preclinical study
- Protein kinase CK2
- protein kinase PIM-1
- pyrazolo [3,4-d]pyrimidine scaffold
- pyrazolo[3,4-d]pyrimidines
- rare disease
- Ras
- rigosertib
- ROR1
- saturation transfer difference NMR
- senolytic
- similarity search
- small molecule
- small molecules
- src
- stress-signaling pathways
- structure–activity-relationship (SAR)
- synergy
- Synthesis
- targeted therapy
- thema EDItEUR::P Mathematics and Science
- thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
- thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSD Molecular biology
- Therapeutic target
- Thyroid cancer
- TPGS
- Treatment
- TTP
- tumor spheroids
- tumor-associated macrophages
- Twist1
- tyrosine kinase
- Tyrosine kinase inhibitors
- UPR
- X-ray crystallography
- zanubrutinib
Links
DOI: 10.3390/books978-3-7258-1289-9Editions